Increased tumor marker ca-125 in multiple myeloma: a case report

Dwiwahyonokusuma ., I. Gede Eka Wiratnaya, Gede Agung Krisna Yudha, I. Gede Mahardika Putra


Multiple myeloma (MM) is a malignant B-cell lymphoproliferative disorder of the marrow, with plasma cells predominating. It is unlikely to encounter rising level of any tumor marker in MM patient. We present a case of 46-year-old female came to the orthopaedic clinic with chief complains of pain on her right arm, left shoulder and right hip after 5 months. The results of the bone survey of these patients showed multiple lytic lesions with a punched-out appearance in calvaria. The expansive lytic mass was seen with cortical destruction in one third proximal metaphysis to diaphysis of humerus with periosteal reaction and surrounding soft tissue mass. The basic metabolic panel (BMP) result of these patient is hipocellular with decrease of erythroid, myeloid, and megakaryocytes activity and there are 30% plasma cells with positive myeloma cells. Therefore, the patient was diagnosed with MM. The laboratory result of these patient also showed elevation of carbohydrate antigen 125 (CA-125) marker to 56 and 92 (normal range is <35). The patient reported herein showed clear signs and symptoms of MM accompanied by elevated level of CA-125 and CA-15.3 tumor markers. Elevated CA-125 values most often are associated with epithelial ovarian cancer, although levels also can be increased in other malignancies such as endometrial, fallopian tube, breast, lung, esophageal, gastric, hepatic, and pancreatic. However, there were no clear mechanism of how a malignant B-cell lymphoproliferative disorder of the marrow stimulates the production of tumor marker such as CA-125.


Multiple myeloma, Tumor marker, CA-125

Full Text:



Al-Farsi K. Multiple myeloma: an update. Oman Med J. 2013;28(1):3.

Bladé J, Fernández de LC, Rosiñol L, Cibeira MT, Jiménez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805-12.

International myeloma working group (IMWG) consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Available at: Accessed on 25th May 2020.

Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21-33.

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:538-48.

Solomon L, Apley AG. Apley’s System of Orthopaedics and Fractures; 2010.

Wang ML, Huang Q, Yang TX. IgE myeloma with elevated level of serum CA-125. J Zhejiang Univ Sci B. 2009;10(7):559-62.

De Larrea CF, Cibeira MT, Vallansot R, Colomo L, Blade J. Increased serum tumor markers (CA125 and CA15.3) in primary plasma cell leukemia: a case report and review of the literature. Clin Lymphoma Myeloma. 2008;8(5):312-4.

Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Family Physician. 2003:68(6):1075-88.